A Prospective Multicenter Post Approval Study of the ReShape™ Integrated Dual Balloon System in Obese Subjects



Status:Active, not recruiting
Conditions:Obesity Weight Loss
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:22 - Any
Updated:3/31/2019
Start Date:September 2016
End Date:December 2019

Use our guide to learn which trials are right for you!

The ReShape Post Approval Study is a prospective multicenter study of the ReShape(TM)
Integrated Dual Balloon System in Obese Subjects.

The ReShape Post Approval Study is a post-approval, multicenter, single arm, open label
clinical study intended to collect valid scientific evidence regarding the safety and
efficacy of the ReShape Dual Balloon as an adjunct to diet and exercise in the treatment of
BMI 30-40 subjects with one or more obesity-related comorbid conditions in a commercial
clinical setting.

Inclusion Criteria:

1. Ages 22 and older

2. Baseline BMI 30 - 40

3. Failed weight reduction with diet and exercise alone

4. One or more obesity-related comorbid conditions

5. If female of child bearing potential, willing to avoid pregnancy during course of
treatment

Exclusion Criteria:

1. Prior gastrointestinal surgery with sequelae, i.e. obstruction, and/or adhesive
peritonitis or known abdominal adhesions

2. Prior open or laparoscopic bariatric surgery.

3. Any inflammatory disease of the gastrointestinal tract including esophagitis, gastric
ulceration, duodenal ulceration, cancer or specific inflammation such as Crohn's
disease.

4. Potential upper gastrointestinal bleeding conditions such as esophageal or gastric
varices, congenital or acquired intestinal telangiectasis, or other congenital
anomalies of the gastrointestinal tract such as atresias or stenoses.

5. A gastric mass.

6. A hiatal hernia > 5 cm or ≤ 5 cm with associated severe or intractable
gastro-esophageal reflux symptoms.

7. A structural abnormality in the esophagus or pharynx such as a stricture or
diverticulum that could impede passage of the delivery catheter and/or an endoscope.

8. Achalasia or any other severe esophageal motility disorder that may pose a safety risk
during the removal of the device

9. Severe coagulopathy

10. Hepatic insufficiency or cirrhosis

11. Serious or uncontrolled psychiatric illness or disorder that could compromise patient
understanding of or compliance with follow up visits and removal of the device after 6
months.

12. Alcoholism or drug addiction.

13. Patients unwilling to participate in an established medically-supervised diet and
behavior modification program, with routine medical follow-up.

14. Patients receiving daily prescribed treatment with aspirin, anti-inflammatory agents,
anticoagulants or other gastric irritants.

15. Patients who are unable or unwilling to take prescribed proton pump inhibitor
medication for the duration of the device implant.

16. Patients who are known to have, or suspected to have, an allergic reaction to
materials contained in the system.

17. Patients who have ever developed a serotonin syndrome and are currently taking any
drug known to affect the levels of serotonin in the body [e.g., selective serotonin
reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs),
monoamine oxidase inhibitors (MAOIs)] should not undergo placement of the device.

18. Patients who are pregnant or breast-feeding.

19. Significant endoscopic abnormalities immediately prior to device insertion.
We found this trial at
14
sites
Shoreline, Washington 98155
Principal Investigator: Peter S Billing, MD
Phone: 425-778-2220
?
mi
from
Shoreline, WA
Click here to add this to my saved trials
27750 West State Route 22
Barrington, Illinois 60010
Principal Investigator: Daniel Wool, MD
?
mi
from
Barrington, IL
Click here to add this to my saved trials
10475 Reading Road
Cincinnati, Ohio 45241
Principal Investigator: Trace Curry, MD
Phone: 513-475-3663
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Dothan, Alabama 36305
Principal Investigator: Travis J Rutland, MD
Phone: 334-836-3341
?
mi
from
Dothan, AL
Click here to add this to my saved trials
Knoxville, Tennessee 37909
Principal Investigator: Bergein F Overholt, MD
Phone: 865-558-0687
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
1211 Coolidge Street
Lafayette, Louisiana 70503
Principal Investigator: Eric Trawick, MD
Phone: 337-232-6697
?
mi
from
Lafayette, LA
Click here to add this to my saved trials
Memphis, Tennessee 38120
Principal Investigator: George Woodman, MD
Phone: 901-869-2000
?
mi
from
Memphis, TN
Click here to add this to my saved trials
Metairie, Louisiana 70001
Principal Investigator: Thomas Lavin, MD
Phone: 504-934-3000
?
mi
from
Metairie, LA
Click here to add this to my saved trials
537 Stanton Christiana Road
Newark, Delaware 19713
Principal Investigator: Isaias Irgau, MD
Phone: 302-892-9900
?
mi
from
Newark, DE
Click here to add this to my saved trials
Roslyn Heights, New York 11577
Principal Investigator: Shawn Garber, MD
Phone: 516-616-5500
?
mi
from
Roslyn Heights, NY
Click here to add this to my saved trials
Saint Louis, Missouri 63110
Principal Investigator: Vladimir Kushnir, MD
Phone: 314-747-1264
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
2094 East State Street
Salem, Ohio 44460
Principal Investigator: Jonathan Pulido, MD
Phone: 330-337-2868
?
mi
from
Salem, OH
Click here to add this to my saved trials
San Antonio, Texas 78240
Principal Investigator: John Pilcher, M.D.
Phone: 210-651-0303
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
309 Engle Street
Teaneck, New Jersey 07666
Principal Investigator: Stefanie Vaimakis, MD
Phone: 201-530-1900
?
mi
from
Teaneck, NJ
Click here to add this to my saved trials